Urinary MHPG, platelet 3H-imipramine binding and symptomatology in depression: an exploratory study of clinical heterogeneity.
Urinary MHPG concentrations and platelet 3H-imipramine binding (Bmax, Kd) were measured in 20 psychiatric inpatients with diagnoses of major depressive disorder. Clinical assessments were performed using the Present State Examination (PSE) interview, and several dimensions of symptomatology were constructed on the basis of the PSE items. There was a significant positive relationship between Bmax and items reflecting both psychomotor retardation and anxiety. Urinary MHPG bore a comparatively complex nonlinear relationship to Bmax and to the psychomotor retardation symptom dimension. Urinary MHPG also showed an inverse, curvilinear correlation with certain neurotic symptoms. The implications of these findings are briefly discussed in the light of the "dysregulation" hypothesis of affective disorder.
Carr
V
V
University of Adelaide, South Australia.
Edwards
J
J
Prior
M
M
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000378:metabolism*; D002352:Carrier Proteins; D003866:Depressive Disorder / Q000378:metabolism / Q000523:psychology*; D005260:Female; D006018:Glycols / Q000652:urine*; D006801:Humans; D007099:Imipramine / Q000493:pharmacokinetics*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D008875:Middle Aged; D011581:Psychological Tests; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000378:metabolism*
D002352:Carrier Proteins; D006018:Glycols; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; C027775:imipramine receptor; D008734:Methoxyhydroxyphenylglycol; D007099:Imipramine